M. Clavel

4.8k total citations
115 papers, 3.6k citations indexed

About

M. Clavel is a scholar working on Oncology, Mechanical Engineering and Materials Chemistry. According to data from OpenAlex, M. Clavel has authored 115 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 33 papers in Mechanical Engineering and 25 papers in Materials Chemistry. Recurrent topics in M. Clavel's work include Cancer Treatment and Pharmacology (23 papers), Microstructure and Mechanical Properties of Steels (13 papers) and High Temperature Alloys and Creep (13 papers). M. Clavel is often cited by papers focused on Cancer Treatment and Pharmacology (23 papers), Microstructure and Mechanical Properties of Steels (13 papers) and High Temperature Alloys and Creep (13 papers). M. Clavel collaborates with scholars based in France, Netherlands and Belgium. M. Clavel's co-authors include Jaap Verweij, A. Pineau, X. Feaugas, Bernard Chevalier, G. Catimel, M. Marty, N Le Bail, René Bruno, Anne‐Laure Helbert and Jean Marc Extra and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Applied Physics and Cancer.

In The Last Decade

M. Clavel

113 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Clavel France 33 1.6k 880 777 607 596 115 3.6k
Paul Van Houtte Belgium 38 2.1k 1.3× 1.8k 2.1× 3.0k 3.8× 1.4k 2.4× 1.4k 2.3× 238 6.6k
Hongyun Zhao China 43 2.7k 1.7× 1.5k 1.7× 1.7k 2.2× 274 0.5× 383 0.6× 321 6.4k
Shinichiro Takahashi Japan 39 2.7k 1.8× 271 0.3× 1.8k 2.3× 353 0.6× 199 0.3× 328 5.7k
Richard J. Stock United States 25 430 0.3× 851 1.0× 287 0.4× 614 1.0× 482 0.8× 67 4.0k
Hai T. Tran United States 42 3.5k 2.3× 262 0.3× 2.9k 3.7× 158 0.3× 257 0.4× 168 7.5k
Zhixing Guo China 34 348 0.2× 2.1k 2.4× 282 0.4× 881 1.5× 807 1.4× 209 3.8k
Andreas Makris United Kingdom 44 2.9k 1.8× 161 0.2× 743 1.0× 255 0.4× 118 0.2× 141 6.4k
Henrik Schmidt Denmark 26 797 0.5× 1.5k 1.7× 244 0.3× 136 0.2× 169 0.3× 115 3.8k
Douglas R. Adkins United States 38 2.3k 1.5× 206 0.2× 1.4k 1.9× 81 0.1× 45 0.1× 264 5.5k
Makoto Murata Japan 30 876 0.6× 440 0.5× 194 0.2× 337 0.6× 143 0.2× 256 3.6k

Countries citing papers authored by M. Clavel

Since Specialization
Citations

This map shows the geographic impact of M. Clavel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Clavel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Clavel more than expected).

Fields of papers citing papers by M. Clavel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Clavel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Clavel. The network helps show where M. Clavel may publish in the future.

Co-authorship network of co-authors of M. Clavel

This figure shows the co-authorship network connecting the top 25 collaborators of M. Clavel. A scholar is included among the top collaborators of M. Clavel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Clavel. M. Clavel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Clavel, M., Alexis Vandel, Vincent Modica, et al.. (2021). Determination of spatially averaged consumption speed from spherical expanding flame: A new experimental methodology. Combustion and Flame. 235. 111720–111720. 3 indexed citations
3.
Peters, Godefridus J., M. Clavel, Paul Noordhuis, et al.. (2007). Clinical Phase I and Pharmacology Study of Gemcitabine (2', 2'-Difluorodeoxycytidine) Administered in a Two-Weekly Schedule. Journal of Chemotherapy. 19(2). 212–221. 36 indexed citations
4.
Mornex, F., L. Thomas, Peter Mohr, et al.. (2003). A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Research. 13(1). 97–103. 104 indexed citations
5.
Bachelot, Thomas, Isabelle Ray‐Coquard, G. Catimel, et al.. (2000). Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Annals of Oncology. 11(2). 151–156. 98 indexed citations
6.
Armand, Jean‐Pierre, et al.. (1996). Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Annals of Oncology. 7(8). 837–842. 29 indexed citations
7.
8.
Clavel, M., et al.. (1995). Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. European Journal of Cancer. 31(1). 15–19. 28 indexed citations
9.
Ravaud, Alain, Sylvie Négrier, Laurent Cany, et al.. (1994). Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. British Journal of Cancer. 69(6). 1111–1114. 31 indexed citations
10.
Catimel, G., Jan B. Vermorken, M. Clavel, et al.. (1994). A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Annals of Oncology. 5(6). 543–547. 108 indexed citations
11.
Verweij, Jaap, M. Clavel, & Bernard Chevalier. (1994). Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind. Annals of Oncology. 5(6). 495–505. 282 indexed citations
12.
Vermorken, J. B., Jaco J. Verweij, F. Cognetti, et al.. (1993). Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC Head and Neck Cancer Cooperative Group. Annals of Oncology. 4(9). 785–788. 69 indexed citations
13.
Clavel, M. & G. Catimel. (1993). Breast cancer: Chemotherapy in the treatment of advanced disease. European Journal of Cancer. 29(4). 598–604. 29 indexed citations
14.
Vermorken, Jan B., S. Gundersen, M. Clavel, et al.. (1993). Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. Annals of Oncology. 4(4). 303–306. 10 indexed citations
15.
Mercatello, A., Philippe Thiesse, Jean‐Yves Blay, et al.. (1992). Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. British Journal of Cancer. 65(5). 723–726. 15 indexed citations
16.
Kaye, Stuart, J. Wanders, M. Clavel, et al.. (1992). Short report: Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma. Annals of Oncology. 3(5). 406–408. 2 indexed citations
17.
Clavel, M.. (1991). Management of breast cancer with bone metastases. Bone. 12. S11–S12. 6 indexed citations
18.
Clavel, M., et al.. (1991). Head and neck cancer: Prognostic factors for response to chemotherapy. European Journal of Cancer and Clinical Oncology. 27(3). 349–356. 11 indexed citations
19.
Philip, Thierry, A. Mercatello, Sylvie Négrier, et al.. (1989). Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients. Cancer Treatment Reviews. 16. 91–104. 22 indexed citations
20.
Beer, M., Franco Cavalli, Stuart Kaye, et al.. (1987). A phase II study of carboplatin in advanced or metastatic stomach cancer. European Journal of Cancer and Clinical Oncology. 23(10). 1565–1567. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Van Houtte Breakdown of academic impact, for papers by Hongyun Zhao Breakdown of academic impact, for papers by Shinichiro Takahashi Breakdown of academic impact, for papers by Richard J. Stock Breakdown of academic impact, for papers by Hai T. Tran Breakdown of academic impact, for papers by Zhixing Guo Breakdown of academic impact, for papers by Andreas Makris Breakdown of academic impact, for papers by Henrik Schmidt Breakdown of academic impact, for papers by Douglas R. Adkins Breakdown of academic impact, for papers by Makoto Murata
Rankless by CCL
2026